Giuseppe
Emeritus
[Source: The Lancet, full text: (LINK). Abstract, edited.]
[Articles] Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial
Wolfgang G?pel, Angela Kribs, Andreas Ziegler, Reinhard Laux, Thomas Hoehn, Christian Wieg, Jens Siegel, Stefan Avenarius, Axel von der Wense, Matthias Vochem, Peter Groneck, Ursula Weller, Jens M?ller, Christoph H?rtel, Sebastian Haller, Bernhard Roth, Egbert Herting
Summary
Background
Surfactant is usually given to mechanically ventilated preterm infants via an endotracheal tube to treat respiratory distress syndrome. We tested a new method of surfactant application to spontaneously breathing preterm infants to avoid mechanical ventilation.
Method
In a parallel-group, randomised controlled trial, 220 preterm infants with a gestational age between 26 and 28 weeks and a birthweight less than 1?5 kg were enrolled in 12 German neonatal intensive care units. Infants were independently randomised in a 1:1 ratio with variable block sizes, to standard treatment or intervention, and randomisation was stratified according to centre and multiple birth status. Masking was not possible. Infants were stabilised with continuous positive airway pressure and received rescue intubation if necessary. In the intervention group, infants received surfactant treatment during spontaneous breathing via a thin catheter inserted into the trachea by laryngoscopy if they needed a fraction of inspired oxygen more than 0?30. The primary endpoint was need for any mechanical ventilation, or being not ventilated but having a partial pressure of carbon dioxide more than 65 mm Hg (8?6 kPa) or a fraction of inspired oxygen more than 0?60, or both, for more than 2 h between 25 h and 72 h of age. Analysis was by intention to treat. This study is registered, number ISRCTN05025922.
Findings
108 infants were assigned to the intervention group and 112 infants to the standard treatment group. All infants were analysed. On day 2 or 3 after birth, 30 (28%) infants in the intervention group were mechanically ventilated versus 51 (46%) in the standard treatment group (number needed to treat 6, 95% CI 3?20, absolute risk reduction 0?18, 95% CI 0?30?0?05, p=0?008). 36 (33%) infants in the intervention group were mechanically ventilated during their stay in the hospital compared with 82 (73%) in the standard treatment group (number needed to treat: 3, 95% CI 2?4, p<0?0001). The intervention group had significantly fewer median days on mechanical ventilation, (0 days. IQR 0?3 vs 2 days, 0?5) and a lower need for oxygen therapy at 28 days (30 infants [30%] vs 49 infants [45%], p=0?032) compared with the standard treatment group. We recorded no differences between groups for mortality (seven deaths in the intervention group vs five in the standard treatment group) and serious adverse events (21 vs 28).
Interpretation
The application of surfactant via a thin catheter to spontaneously breathing preterm infants receiving continuous positive airway pressure reduces the need for mechanical ventilation.
Funding
German Ministry of Research and Technology, University of L?beck, and Chiesi Pharmaceuticals.
- -------Wolfgang G?pel, Angela Kribs, Andreas Ziegler, Reinhard Laux, Thomas Hoehn, Christian Wieg, Jens Siegel, Stefan Avenarius, Axel von der Wense, Matthias Vochem, Peter Groneck, Ursula Weller, Jens M?ller, Christoph H?rtel, Sebastian Haller, Bernhard Roth, Egbert Herting
Summary
Background
Surfactant is usually given to mechanically ventilated preterm infants via an endotracheal tube to treat respiratory distress syndrome. We tested a new method of surfactant application to spontaneously breathing preterm infants to avoid mechanical ventilation.
Method
In a parallel-group, randomised controlled trial, 220 preterm infants with a gestational age between 26 and 28 weeks and a birthweight less than 1?5 kg were enrolled in 12 German neonatal intensive care units. Infants were independently randomised in a 1:1 ratio with variable block sizes, to standard treatment or intervention, and randomisation was stratified according to centre and multiple birth status. Masking was not possible. Infants were stabilised with continuous positive airway pressure and received rescue intubation if necessary. In the intervention group, infants received surfactant treatment during spontaneous breathing via a thin catheter inserted into the trachea by laryngoscopy if they needed a fraction of inspired oxygen more than 0?30. The primary endpoint was need for any mechanical ventilation, or being not ventilated but having a partial pressure of carbon dioxide more than 65 mm Hg (8?6 kPa) or a fraction of inspired oxygen more than 0?60, or both, for more than 2 h between 25 h and 72 h of age. Analysis was by intention to treat. This study is registered, number ISRCTN05025922.
Findings
108 infants were assigned to the intervention group and 112 infants to the standard treatment group. All infants were analysed. On day 2 or 3 after birth, 30 (28%) infants in the intervention group were mechanically ventilated versus 51 (46%) in the standard treatment group (number needed to treat 6, 95% CI 3?20, absolute risk reduction 0?18, 95% CI 0?30?0?05, p=0?008). 36 (33%) infants in the intervention group were mechanically ventilated during their stay in the hospital compared with 82 (73%) in the standard treatment group (number needed to treat: 3, 95% CI 2?4, p<0?0001). The intervention group had significantly fewer median days on mechanical ventilation, (0 days. IQR 0?3 vs 2 days, 0?5) and a lower need for oxygen therapy at 28 days (30 infants [30%] vs 49 infants [45%], p=0?032) compared with the standard treatment group. We recorded no differences between groups for mortality (seven deaths in the intervention group vs five in the standard treatment group) and serious adverse events (21 vs 28).
Interpretation
The application of surfactant via a thin catheter to spontaneously breathing preterm infants receiving continuous positive airway pressure reduces the need for mechanical ventilation.
Funding
German Ministry of Research and Technology, University of L?beck, and Chiesi Pharmaceuticals.